147 related articles for article (PubMed ID: 16271794)
1. Hepatitis C minimal residual viremia (MRV) detected by TMA at the end of Peg-IFN plus ribavirin therapy predicts post-treatment relapse.
Gerotto M; Dal Pero F; Bortoletto G; Ferrari A; Pistis R; Sebastiani G; Fagiuoli S; Realdon S; Alberti A
J Hepatol; 2006 Jan; 44(1):83-7. PubMed ID: 16271794
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia.
Zeuzem S; Buti M; Ferenci P; Sperl J; Horsmans Y; Cianciara J; Ibranyi E; Weiland O; Noviello S; Brass C; Albrecht J
J Hepatol; 2006 Jan; 44(1):97-103. PubMed ID: 16290907
[TBL] [Abstract][Full Text] [Related]
3. Prognostic significance of hepatitis C virus RNA detection by transcription-mediated amplification with negative polymerase chain reaction during therapy with peginterferon alpha and ribavirin.
Kadam JS; Gonzalez SA; Ahmed F; Menezes A; Jacobson IM
Dig Dis Sci; 2007 Oct; 52(10):2525-30. PubMed ID: 17406826
[TBL] [Abstract][Full Text] [Related]
4. Discordance between HCV RNA assays for week 24 HCV RNA determination during pegylated interferon-α/ribavirin treatment for chronic hepatitis C.
Roomer R; van Vuuren AJ; Schutten M; Heijens A; Janssen HL; de Knegt RJ
Antivir Ther; 2011; 16(5):771-4. PubMed ID: 21817199
[TBL] [Abstract][Full Text] [Related]
5. Antiviral re-treatment of IFN-ribavirin non-responders for recurrent post-transplantation hepatitis C.
Yedibela S; Demir R; Melling N; Aydin Ü; Schuppan D; Müller V; Hohenberger W; Schönleben F
Clin Transplant; 2011; 25(1):131-5. PubMed ID: 20438578
[TBL] [Abstract][Full Text] [Related]
6. HCV RNA detection by TMA during the hepatitis C antiviral long-term treatment against cirrhosis (Halt-C) trial.
Morishima C; Morgan TR; Everhart JE; Wright EC; Shiffman ML; Everson GT; Lindsay KL; Lok AS; Bonkovsky HL; Di Bisceglie AM; Lee WM; Dienstag JL; Ghany MG; Gretch DR;
Hepatology; 2006 Aug; 44(2):360-7. PubMed ID: 16871570
[TBL] [Abstract][Full Text] [Related]
7. Predictive value of early virological response to treatment with different interferon-based regimens plus ribavirin in patients with chronic hepatitis C.
Napoli N; Giannelli G; Parisi CV; Antonaci A; Maddalena G; Antonaci S
New Microbiol; 2005 Jan; 28(1):13-21. PubMed ID: 15782622
[TBL] [Abstract][Full Text] [Related]
8. Prediction of minimal residual viremia in HCV type 1 infected patients receiving interferon-based therapy.
Knop V; Teuber G; Klinker H; Möller B; Rasenack J; Hinrichsen H; Gerlach T; Spengler U; Buggisch P; Neumann K; Sarrazin C; Zeuzem S; Berg T
Ann Hepatol; 2013; 12(2):190-8. PubMed ID: 23396729
[TBL] [Abstract][Full Text] [Related]
9. Early HCV RNA changes in patients with chronic hepatitis C treated with peginterferon alfa 2b and ribavirin.
Gallegos-Orozco JF; Fuentes AP; Olivera-Martinez MA; Gutiérrez-Reyes G; Cortina D; Oregel JA; Pérez-Pruna C; Sixtos MS; Cruz-Castellanos S; Soto-Ramírez LE; Rodríguez-Díaz R; Fuentes-Romero L; Gutiérrez-Ruiz MC; Kershenobich D
Rev Invest Clin; 2003; 55(2):138-42. PubMed ID: 12827916
[TBL] [Abstract][Full Text] [Related]
10. Pegylated-interferon alpha 2b and ribavirin for recurrent hepatitis C after liver transplantation: From a Canadian experience to recommendations for therapy.
Babatin M; Schindel L; Burak KW
Can J Gastroenterol; 2005 Jun; 19(6):359-65. PubMed ID: 15997269
[TBL] [Abstract][Full Text] [Related]
11. Role of rapid virological response in prediction of sustained virological response to Peg-IFN plus ribavirin in HCV / HIV co-infected individuals.
Shea DO; Tuite H; Farrell G; Codd M; Mulcahy F; Norris S; Bergin C
J Viral Hepat; 2008 Jul; 15(7):482-9. PubMed ID: 18221297
[TBL] [Abstract][Full Text] [Related]
12. Peginterferon-alfa2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment.
Sánchez-Tapias JM; Diago M; Escartín P; Enríquez J; Romero-Gómez M; Bárcena R; Crespo J; Andrade R; Martínez-Bauer E; Pérez R; Testillano M; Planas R; Solá R; García-Bengoechea M; Garcia-Samaniego J; Muñoz-Sánchez M; Moreno-Otero R;
Gastroenterology; 2006 Aug; 131(2):451-60. PubMed ID: 16890599
[TBL] [Abstract][Full Text] [Related]
13. Assessment, by transcription-mediated amplification, of virologic response in patients with chronic hepatitis C virus treated with peginterferon alpha-2a.
Sarrazin C; Hendricks DA; Sedarati F; Zeuzem S
J Clin Microbiol; 2001 Aug; 39(8):2850-5. PubMed ID: 11474002
[TBL] [Abstract][Full Text] [Related]
14. Peginterferon alpha-2a (40 KD) plus ribavirin for the treatment of chronic hepatitis C in Japanese patients.
Kuboki M; Iino S; Okuno T; Omata M; Kiyosawa K; Kumada H; Hayashi N; Sakai T
J Gastroenterol Hepatol; 2007 May; 22(5):645-52. PubMed ID: 17444850
[TBL] [Abstract][Full Text] [Related]
15. The use of different Peg-interferon alpha-2b regimens plus ribavirin in HCV-1b-infected patients after rapid virological response does not affect the achievement of sustained virological response.
Napoli N; Giannelli G; Antonaci A; Antonaci S
J Viral Hepat; 2008 Apr; 15(4):300-4. PubMed ID: 18307592
[TBL] [Abstract][Full Text] [Related]
16. Predictors of viral kinetics to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b.
Akuta N; Suzuki F; Kawamura Y; Yatsuji H; Sezaki H; Suzuki Y; Hosaka T; Kobayashi M; Kobayashi M; Arase Y; Ikeda K; Kumada H
J Med Virol; 2007 Nov; 79(11):1686-95. PubMed ID: 17854035
[TBL] [Abstract][Full Text] [Related]
17. Assessment of hepatitis C virus-RNA clearance under combination therapy for hepatitis C virus genotype 1: performance of the transcription-mediated amplification assay.
Ferraro D; Giglio M; Bonura C; Di Marco V; Mondelli MU; Craxì A; Di Stefano R
J Viral Hepat; 2008 Jan; 15(1):66-70. PubMed ID: 18088247
[TBL] [Abstract][Full Text] [Related]
18. Undetectable hepatitis C virus RNA at week 4 as predictor of sustained virological response in HIV patients with chronic hepatitis C.
Martin-Carbonero L; Nuñez M; Mariño A; Alcocer F; Bonet L; García-Samaniego J; López-Serrano P; Cordero M; Portu J; Soriano V
AIDS; 2008 Jan; 22(1):15-21. PubMed ID: 18090387
[TBL] [Abstract][Full Text] [Related]
19. Predictive value of rapid virological response and early virological response on sustained virological response in HCV patients treated with pegylated interferon alpha-2a and ribavirin.
Yu JW; Wang GQ; Sun LJ; Li XG; Li SC
J Gastroenterol Hepatol; 2007 Jun; 22(6):832-6. PubMed ID: 17565637
[TBL] [Abstract][Full Text] [Related]
20. Prediction of sustained virological response in liver transplant recipients with recurrent hepatitis C virus following combination pegylated interferon alfa-2b and ribavirin therapy using tissue hepatitis C virus reverse transcriptase polymerase chain reaction testing.
Neff GW; O'Brien CB; Cirocco R; Montalbano M; de Medina M; Ruiz P; Khaled AS; Bejarano PA; Safdar K; Hill MA; Tzakis AG; Schiff ER
Liver Transpl; 2004 May; 10(5):595-8. PubMed ID: 15108250
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
